Condition
Treatment-Refractory Solid Tumors
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (3)
Trial Status
Recruiting1
Withdrawn1
Not Yet Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07190833Phase 1RecruitingPrimary
A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)
NCT07170592Phase 1Not Yet RecruitingPrimary
A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients
NCT05655598Phase 1Withdrawn
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
Showing all 3 trials